Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Angioedema

• A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
• Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
• A Study of STAR-0215 in Participants With Hereditary Angioedema
• Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients
• PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
• An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
• A Study of STAR-0215 in Healthy Adult Participants
• A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)
• Berotralstat Treatment in Children With Hereditary Angioedema
• Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
• A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
• A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
• A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers
• OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)
• Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations
• A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II
• Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II
• Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies
• Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema
• Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema
• CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks
• A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema
• Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
• A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor
• A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 in Healthy Volunteers
• An Extension Study of IONIS-PKK-LRx in Participants With Hereditary Angioedema
• A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II
• A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
• Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)
• A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children
• A Study to Assess the Clinical Efficacy of IONIS-PKK-LRx in Participants With Hereditary Angioedema
• A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants
• Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan
• Dupilumab in Chronic Spontaneous Urticaria
• A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)
• COrticosteroids in acUte uRticAria in emerGency dEpartment
• Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
• A Long Term Safety Study of BCX7353 in Hereditary Angioedema
• Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema
• A Relative Bioavailability Study of Two Formulations of BCX7353
• A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions
• Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy
• Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema
• Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)
• An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates
• Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
• Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema
• Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects
• Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
• Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
• First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers
• 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
• Study to Determine How BCX4161 is Metabolized and Eliminated by the Body
• A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161
• A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants
• Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers
• Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE
• A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects
• Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema
• Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema
• Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema
• EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema
• Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy
• Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema
• Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE
• Pharmacogenetics of Ace Inhibitor-Associated Angioedema
• C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks
• A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
• The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment
• Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
• Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
• Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
• AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study
• C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation
• Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
• Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
• C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks
• EASSI - Evaluation of the Safety of Self-Administration With Icatibant
• A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)
• A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis
• A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration
• Berinert P Study of Subcutaneous Versus Intravenous Administration
• Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema
• Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)
• Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)
• Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
• Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects
• C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)
• C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks
• Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
• Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
• Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)
• Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
• Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
• C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema
• C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema
• Kinetics, Efficacy and Safety of C1-Esteraseremmer-N
• Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema
• Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations